Strand Therapeutics
Wen Allen Tseng is a Principal Scientist at Strand Therapeutics since October 2021, focusing on the development of advanced mRNA therapeutics utilizing synthetic biology to selectively target and destroy cancer cells. Previously, Wen served as a Principal Scientist, Senior Scientist, and Scientist at Solid Biosciences from September 2018 to October 2021, addressing the challenges of Duchenne muscular dystrophy. Wen's earlier experience includes a Postdoctoral Associate position at the Massachusetts Institute of Technology (MIT) from October 2014 to September 2018, where expertise in genetic systems and gene expression control was developed. Wen completed a PhD in Biological and Biomedical Sciences at Harvard University from 2007 to 2014, investigating the NLRP3 inflammasome's role in retinal diseases, and earned a Bachelor of Science in Biological Sciences from the University of Delaware in 2007.
This person is not in any teams
Strand Therapeutics
3 followers
Strand was started by biological engineers working together at MIT. Building on the idea of creating smart therapies that are capable of making sophisticated decisions, they sought to apply the concept of the emerging field of mRNA therapeutics.